In a review of previous studies, McMaster University researchers observe a stronger signal for psilocybin as a treatment for obsessive-compulsive disorder than cannabinoids.
Distractify on MSNOpinion
Psychedelic researcher questions industry's rush to market
Johns Hopkins trial veteran warns venture capital threatens therapeutic integrity as psilocybin nears FDA approval ...
A new UBC Okanagan study found that people who microdose psychedelics feel better on the days they take them—but those boosts don't seem to last.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback